Upjohn patents expiration
1. Celebrex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5466823 | UPJOHN | Substituted pyrazolyl benzenesulfonamides |
Nov, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5563165 | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Nov, 2013
(10 years ago) | |
|
US5466823 (Pediatric) | UPJOHN | Substituted pyrazolyl benzenesulfonamides |
May, 2014
(9 years ago) | |
|
US5563165 (Pediatric) | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
May, 2014
(9 years ago) | |
| USRE44048 | UPJOHN | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
Jun, 2015
(8 years ago) | |
| US5760068 | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Jun, 2015
(8 years ago) | |
|
US5760068 (Pediatric) | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Dec, 2015
(8 years ago) | |
|
USRE44048 (Pediatric) | UPJOHN | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
Dec, 2015
(8 years ago) | |
Drugs and Companies using CELECOXIB ingredient
Market Authorisation Date: 15 December, 2006
Treatment: Treatment of ankylosing spondylitis; Treatment of inflammation or an inflammation-associated disorder
Dosage: CAPSULE;ORAL
CELEBREX family patents
2. Detrol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5382600 (Pediatric) | UPJOHN | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
Sep, 2012
(11 years ago) | |
Drugs and Companies using TOLTERODINE TARTRATE ingredient
Market Authorisation Date: 25 March, 1998
Treatment: NA
Dosage: TABLET;ORAL
DETROL family patents
3. Detrol La patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5382600 (Pediatric) | UPJOHN | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
Sep, 2012
(11 years ago) | |
| US6770295 | UPJOHN | Therapeutic formulation for administering tolterodine with controlled release |
Aug, 2019
(4 years ago) | |
| US6630162 | UPJOHN | Pharmaceutical formulation and its use |
Nov, 2019
(4 years ago) | |
| US6911217 | UPJOHN | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
Nov, 2019
(4 years ago) | |
|
US6770295 (Pediatric) | UPJOHN | Therapeutic formulation for administering tolterodine with controlled release |
Feb, 2020
(4 years ago) | |
|
US6630162 (Pediatric) | UPJOHN | Pharmaceutical formulation and its use |
May, 2020
(3 years ago) | |
|
US6911217 (Pediatric) | UPJOHN | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
May, 2020
(3 years ago) | |
Drugs and Companies using TOLTERODINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2000
Treatment: Treatment of overactive bladder. treatment of urinary incontinence.
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
DETROL LA family patents
4. Effexor Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6444708 | UPJOHN | Treatment using venlafaxine |
Jun, 2013
(10 years ago) | |
| US5916923 | UPJOHN | Venlafaxine for the treatment of generalized anxiety disorder |
Jun, 2013
(10 years ago) | |
| US6310101 | UPJOHN | Treatments using venlafaxine |
Jun, 2013
(10 years ago) | |
|
US6444708 (Pediatric) | UPJOHN | Treatment using venlafaxine |
Dec, 2013
(10 years ago) | |
|
US5916923 (Pediatric) | UPJOHN | Venlafaxine for the treatment of generalized anxiety disorder |
Dec, 2013
(10 years ago) | |
| US6274171 | UPJOHN | Extended release formulation of venlafaxine hydrochloride |
Mar, 2017
(7 years ago) | |
| US6403120 | UPJOHN | Extended release formulation of venlafaxine hydrochloride |
Mar, 2017
(7 years ago) | |
| US6419958 | UPJOHN | Extended release formulation of venlafaxine hydrochloride |
Mar, 2017
(7 years ago) | |
|
US6274171 (Pediatric) | UPJOHN | Extended release formulation of venlafaxine hydrochloride |
Sep, 2017
(6 years ago) | |
|
US6419958 (Pediatric) | UPJOHN | Extended release formulation of venlafaxine hydrochloride |
Sep, 2017
(6 years ago) | |
|
US6403120 (Pediatric) | UPJOHN | Extended release formulation of venlafaxine hydrochloride |
Sep, 2017
(6 years ago) | |
Drugs and Companies using VENLAFAXINE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 October, 1997
Treatment: Treatment of generalized anxiety disorder; Treatment of panic disorder; Treatment of depression and generalized anxiety disorder
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
EFFEXOR XR family patents
5. Inspra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6410524 | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
Nov, 2019
(4 years ago) | |
| US6747020 | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
Nov, 2019
(4 years ago) | |
| US6410054 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(4 years ago) | |
| US6534093 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(4 years ago) | |
| US7157101 | UPJOHN | Micronized eplerenone compositions |
Dec, 2019
(4 years ago) | |
| US6495165 | UPJOHN | Eplerenone compositions having improved bioavailability |
Dec, 2019
(4 years ago) | |
| US6558707 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(4 years ago) | |
| US6863902 | UPJOHN | Immediate release eplerenone compositions |
Apr, 2020
(4 years ago) | |
|
US6410524 (Pediatric) | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
May, 2020
(3 years ago) | |
|
US6747020 (Pediatric) | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
May, 2020
(3 years ago) | |
|
US7157101 (Pediatric) | UPJOHN | Micronized eplerenone compositions |
Jun, 2020
(3 years ago) | |
|
US6410054 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(3 years ago) | |
|
US6558707 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(3 years ago) | |
|
US6534093 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(3 years ago) | |
|
US6495165 (Pediatric) | UPJOHN | Eplerenone compositions having improved bioavailability |
Jun, 2020
(3 years ago) | |
|
US6863902 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Oct, 2020
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jul 31, 2011 |
Drugs and Companies using EPLERENONE ingredient
Market Authorisation Date: 27 September, 2002
Treatment: Use of eplerenone in combination with an angiotensin converting enzyme (ace) inhibitor for treating hypertension; Use of eplerenone in combination with an angiotensin converting enzyme (ace) inhibitor...
Dosage: TABLET;ORAL
INSPRA family patents
6. Lipitor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5969156 | UPJOHN | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jul, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6126971 | UPJOHN | Stable oral CI-981 formulation and process for preparing same |
Jan, 2013
(11 years ago) | |
|
US6126971 (Pediatric) | UPJOHN | Stable oral CI-981 formulation and process for preparing same |
Jul, 2013
(10 years ago) | |
| US5686104 | UPJOHN | Stable oral CI-981 formulation and process of preparing same |
Nov, 2014
(9 years ago) | |
|
US5686104 (Pediatric) | UPJOHN | Stable oral CI-981 formulation and process of preparing same |
May, 2015
(8 years ago) | |
|
US5969156 (Pediatric) | UPJOHN | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jan, 2017
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-204) | Jun 23, 2020 |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 17 December, 1996
Treatment: Method of inhibiting cholesterol biosynthesis and treating hypercholesterolemia and method for treating hyperlipidemia
Dosage: TABLET;ORAL
LIPITOR family patents
7. Lyrica patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5563175 | UPJOHN | GABA and L-glutamic acid analogs for antiseizure treatment |
Oct, 2013
(10 years ago) | |
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(5 years ago) | |
| US6001876 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(5 years ago) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(4 years ago) | |
|
US6001876 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(4 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-193) | Dec 22, 2019 |
| Pediatric Exclusivity(PED) | Nov 23, 2022 |
| New Patient Population(NPP) | May 23, 2022 |
| New Indication(I-651) | Jun 20, 2015 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 30 December, 2004
Treatment: Treatment of seizure disorder; Treatment of pain, including neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, postherpetic neuralgia, and fibromyalgia; Management ...
Dosage: CAPSULE;ORAL; SOLUTION;ORAL
LYRICA family patents
8. Lyrica Cr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(5 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(4 years ago) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(4 years ago) | |
| US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(2 years from now) | |
| US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(2 years from now) | |
| US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(2 years from now) | |
|
US9144559 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(3 years from now) | |
|
US8945620 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(3 years from now) | |
|
US10022447 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2020 |
| Pediatric Exclusivity(PED) | Apr 11, 2021 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE;ORAL
LYRICA CR family patents
9. Relpax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5545644 | UPJOHN | Indole derivatives |
Dec, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6110940 | UPJOHN | Salts of an anti-migraine indole derivative |
Aug, 2017
(6 years ago) | |
Drugs and Companies using ELETRIPTAN HYDROBROMIDE ingredient
Market Authorisation Date: 26 December, 2002
Treatment: Treatment of migraine with or without aura
Dosage: TABLET;ORAL
RELPAX family patents